Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A novel kinase inhibitor for b-catenin mutant hepatocellular carcinoma [RNA-seq]

ABSTRACT: A novel kinase inhibitor for b-catenin mutant hepatocellular carcinoma [RNA-seq]

PROVIDER: PRJNA881285 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR21604046.fastq.gz	Fastqsanger.gz
	SRR21604047.fastq.gz	Fastqsanger.gz
	SRR21604048.fastq.gz	Fastqsanger.gz
	SRR21604049.fastq.gz	Fastqsanger.gz
	SRR21604050.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 16

Similar Datasets

A novel kinase inhibitor for b-catenin mutant hepatocellular carcinoma II

Project description:A novel kinase inhibitor for b-catenin mutant hepatocellular carcinoma II

| PRJNA881265 | ENA

A novel kinase inhibitor for b-catenin mutant hepatocellular carcinoma [Cut&Run]

Project description:A novel kinase inhibitor for b-catenin mutant hepatocellular carcinoma [Cut&Run]

| PRJNA881282 | ENA

Oncogenic Serine-Threonine Kinase Receptor Associated Protein Supports Hepatocellular Carcinoma Cell Growth by Enhancing Wnt/β-catenin Signaling

Project description:Serine-threonine kinase receptor-associated protein (STRAP) is upregulated in breast, colorectal and lung cancers, promoting their growth. We identify the upregulation of STRAP in hepatocellular carcinomas. Elevated STRAP endows tumor cells with growth advantage by reprograming a variety of metabolic processes and signaling pathways critical for hepatocellular carcinoma progression. Especially, enhanced Wnt/β-catenin signaling is likely to be a major effector of its tumor-promoting role.

2018-09-03 | GSE101061 | GEO

WNTinib is a multi-kinase inhibitor with specificity against β-catenin mutant hepatocellular carcinoma.

Project description:Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide. β-Catenin (CTNNB1)-mutated HCC represents 30% of cases of the disease with no precision therapeutics available. Using chemical libraries derived from clinical multi-kinase inhibitor (KI) scaffolds, we screened HCC organoids to identify WNTinib, a KI with exquisite selectivity in CTNNB1-mutated human and murine models, including patient samples. Multiomic and target engagement analyses, combined with rescue experiments and in vitro and in vivo efficacy studies, revealed that WNTinib is superior to clinical KIs and inhibits KIT/mitogen-activated protein kinase (MAPK) signaling at multiple nodes. Moreover, we demonstrate that reduced engagement on BRAF and p38α kinases by WNTinib relative to several multi-KIs is necessary to avoid compensatory feedback signaling-providing a durable and selective transcriptional repression of mutant β-catenin/Wnt targets through nuclear translocation of the EZH2 transcriptional repressor. Our studies uncover a previously unknown mechanism to harness the KIT/MAPK/EZH2 pathway to potently and selectively antagonize CTNNB1-mutant HCC with an unprecedented wide therapeutic index.

| S-EPMC10948969 | biostudies-literature

A novel kinase inhibitor for b-catenin mutant hepatocellular carcinoma II

Project description:This SuperSeries is composed of the SubSeries listed below.

2023-05-03 | GSE213518 | GEO

Activation of beta-catenin in hepatocellular carcinoma (mouse Ctnnb1 knockout)

2014-12-31 | GSE43628 | GEO

A novel kinase inhibitor for b-catenin mutant hepatocellular carcinoma [Cut&Run]

2023-05-03 | GSE213515 | GEO

A novel kinase inhibitor for b-catenin mutant hepatocellular carcinoma [RNA-seq]

Project description:We screened HCC organoids to identify a CTNNB1-mutant HCC selective small molecule (WNTinib), with MOA depending on reactivation of cytoplasmic EZH2, leading to its nuclear translocation and selective transcriptional block of WNT targets We then performed gene expression profiling analysis using data obtained from RNA-seq of 2 genetically different organoids at 3 time points.

2023-05-03 | GSE213517 | GEO

Tyrosine Kinase Inhibitor Cardiotoxicity

Project description:Tyrosine Kinase Inhibitor Cardiotoxicity

| PRJNA352077 | ENA

Activation of beta-catenin in hepatocellular carcinoma (HCC patients)

Project description:CTNNB1 is the most frequently mutated gene in hepatocellular carcinoma (HCC). However, its clinical relevance remains controversial. We determined an evolutionarily conserved β-catenin signature by comparative analysis of gene expression data from human HCC and a mouse model (GSE43628). We generated gene expression data from the tumors of 88 HCC patients who underwent surgical resection as the primary treatment. We used these gene expression data to develop a new prognostification model for prognosis of HCC after surgery. We generated gene expression data from the tumors of 88 HCC patients who underwent surgical resection as the primary treatment.

2015-05-21 | E-GEOD-43619 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data